Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical
decisions in cancer care, they have limited ability to identify the transcriptional programs that …

Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …

Prostate cancer is the most common non-cutaneous cancer and the second leading cause
of cancer-associated deaths among men in the United States. Androgen deprivation therapy …

Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate
cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic …

Lineage plasticity and histologic transformation to small cell neuroendocrine prostate cancer
(NEPC) is an increasingly recognized mechanism of treatment resistance in advanced …

Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with
phenotypic subtypes that drive therapy response and outcome differences. Histologic …

Androgen receptor (AR) and its splice variants (AR-SVs) promote prostate cancer (PCa)
growth by orchestrating transcriptional reprogramming. Mechanisms by which the low …